Advanced cell-free protein synthesis technology CFPS+ for antibiotic-free expression
CFPS+ by GMES offers a scalable, cost-effective, and antibiotic-free cell-free protein synthesis solution. It ensures high yield and fidelity, eliminating AMR genes and antibiotic residues, making it ideal for safe protein expression.
Overview
General Molecular Expression Service Pty Ltd (GMES) presents CFPS+, an advanced cell-free protein synthesis technology that revolutionizes protein and macromolecule expression. CFPS+ is designed to deliver high-yield, low-cost, and scalable solutions without the use of antibiotics or AMR genes, ensuring a safe and contamination-free product. This makes it an ideal choice for industries requiring stringent safety standards and high-fidelity protein production.
Technical specifications
- Antibiotic-free process: CFPS+ operates without the need for antibiotics or AMR genes, ensuring no antibiotic residues in the final product.
- High fidelity and yield: Eliminates all DNA & RNA from lysate before gene of interest (GOI) input, ensuring exclusive transcription/translation (TX/TL) of the GOI.
- Scalability and cost-effectiveness: Easily scalable to meet various production needs while maintaining low costs.
- Wild-type sourced elements: Utilizes wild-type bacterial components, removing the need for strain selection or recombination screening.
- Contamination-free: No risk of animal transmissible diseases or pathogen contamination.
Technology readiness level
CFPS+ is currently at Technology Readiness Level 5, with the first version commercially viable and ongoing R&D efforts to enhance future versions. GMES offers potential partnerships in co-R&D and licensing for further development, alongside access to downstream processing technologies through collaborations with Neopuriph, Uni Adelaide, and BOKU.
About General Molecular Expression Service Pty Ltd (GMES))
General Molecular Expression Service Pty Ltd (GMES), known as GMExpression, is a biotechnology company incorporated in 2021 and based at the University of Adelaide’s Waite Campus. The company specializes in the development of cell-free protein expression systems, including its proprietary CFPS+ platform. This technology is designed as a low-cost, efficient, and scalable solution for the production of proteins and functional macromolecules. GMES offers a range of services from lab-scale synthesis to large-scale industrial production, supporting complex processes such as codon optimization, protein folding prediction, and purification. Their technological approach integrates advanced metabolic subsystems, including artificial mitochondria and nucleotide anabolic pathways, to enable dynamic and continuous flow production.
The company provides critical infrastructure and materials for researchers, medical applications, and material science, including the synthesis of toxic or difficult-to-express proteins. Beyond its core protein expression services, GMES maintains an online shop supplying laboratory reagents, specialized culture media, and kits such as its Pichia pastoris expression system. Through research collaborations, the company is also expanding into iPSC-derived therapies, organoids, and innovative cultivation protocols. GMES leverages its own commercial profits to support research and development initiatives, often partnering with academic institutions and scholars to advance biotechnological innovation.
delivered to your inbox.